AN2 Therapeutics, Inc.
ANTX
$4.27
-$0.45-9.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.46% | 44.01% | 42.19% | 31.31% | 20.72% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.31% | 7.00% | 10.86% | 2.23% | -9.82% |
| Change in Net Operating Assets | 105.48% | 80.67% | -189.07% | -254.73% | -151.34% |
| Cash from Operations | 39.43% | 51.07% | 41.65% | 28.67% | 7.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -48.14% | -76.96% | 239.26% | 234.50% | 226.14% |
| Cash from Investing | -48.14% | -76.96% | 239.26% | 234.50% | 226.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.62% | -69.62% | -99.87% | -99.90% | -99.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -69.62% | 121.57% | -99.87% | -99.90% | -99.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -124.72% | -1,845.61% | 39.12% | -133.53% | 149.29% |